Literature DB >> 18973947

Complementarity determining regions of an anti-prion protein scFv fragment orchestrate conformation specificity and antiprion activity.

Andreas Müller-Schiffmann1, Benjamin Petsch, S Rutger Leliveld, Janine Muyrers, Agnieska Salwierz, Christian Mangels, Stephan Schwarzinger, Detlev Riesner, Lothar Stitz, Carsten Korth.   

Abstract

The prion protein, PrP, exists in several stable conformations, with the presence of one conformation, PrP(Sc), associated with transmissible neurodegenerative diseases. Targeting PrP by high-affinity ligands has been proven to be an effective way of preventing peripheral prion infections. Here, we have generated bacterially expressed single chain fragments of the variable domains (scFv) of a monoclonal antibody in Escherichia coli, originally raised against purified PrP(Sc) that recognizes both PrP(C) and PrP(Sc). This scFv fragment had a dissociation constant (K(D)) with recombinant PrP of 2 nM and cleared prions in ScN2a cells at 4 nM, as demonstrated by a mouse prion bioassay. A peptide corresponding to the complementarity determining region 3 of the heavy chain (CDR3H) selectively bound PrP(Sc) but had lost antiprion activity. However, synthesis and application of an improved peptide mimicking side chain topology of CDR3H while exhibiting increased protease resistance, a retro-inverso d-peptide of CDR3H, still bound PrP(Sc) and reinstated antiprion activity. We conclude that (1) scFvW226 is so far the smallest polypeptide with bioassay confirmed antiprion activity, and (2) differential conformation specificity and bioactivity can be regulated by orchestrating the participation of different CDRs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973947     DOI: 10.1016/j.molimm.2008.07.023

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  10 in total

1.  Energy landscape of the prion protein helix 1 probed by metadynamics and NMR.

Authors:  Carlo Camilloni; Daniel Schaal; Kristian Schweimer; Stephan Schwarzinger; Alfonso De Simone
Journal:  Biophys J       Date:  2012-01-03       Impact factor: 4.033

2.  Superparamagnetic nanoparticle capture of prions for amplification.

Authors:  Michael B Miller; Surachai Supattapone
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

3.  Enhanced prion detection in biological samples by magnetic particle extraction and real-time quaking-induced conversion.

Authors:  Nathaniel D Denkers; Davin M Henderson; Candace K Mathiason; Edward A Hoover
Journal:  J Gen Virol       Date:  2016-05-27       Impact factor: 3.891

4.  Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling.

Authors:  Wei Hu; Stefan Nessler; Bernhard Hemmer; Todd N Eagar; Lawrence P Kane; S Rutger Leliveld; Andreas Müller-Schiffmann; Anne R Gocke; Amy Lovett-Racke; Li-Hong Ben; Rehana Z Hussain; Andreas Breil; Jeffrey L Elliott; Krishna Puttaparthi; Petra D Cravens; Mahendra P Singh; Benjamin Petsch; Lothar Stitz; Michael K Racke; Carsten Korth; Olaf Stüve
Journal:  Brain       Date:  2010-02-09       Impact factor: 13.501

5.  Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions.

Authors:  Benjamin Petsch; Andreas Müller-Schiffmann; Anna Lehle; Elizabeta Zirdum; Ingrid Prikulis; Franziska Kuhn; Alex J Raeber; James W Ironside; Carsten Korth; Lothar Stitz
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

Review 6.  Prion protein-specific antibodies-development, modes of action and therapeutics application.

Authors:  Tihana Lenac Rovis; Giuseppe Legname
Journal:  Viruses       Date:  2014-10-01       Impact factor: 5.048

7.  Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies.

Authors:  Luise Linsenmeier; Behnam Mohammadi; Mohsin Shafiq; Karl Frontzek; Julia Bär; Amulya N Shrivastava; Markus Damme; Feizhi Song; Alexander Schwarz; Stefano Da Vela; Tania Massignan; Sebastian Jung; Angela Correia; Matthias Schmitz; Berta Puig; Simone Hornemann; Inga Zerr; Jörg Tatzelt; Emiliano Biasini; Paul Saftig; Michaela Schweizer; Dmitri Svergun; Ladan Amin; Federica Mazzola; Luca Varani; Simrika Thapa; Sabine Gilch; Hermann Schätzl; David A Harris; Antoine Triller; Marina Mikhaylova; Adriano Aguzzi; Hermann C Altmeppen; Markus Glatzel
Journal:  Sci Adv       Date:  2021-11-24       Impact factor: 14.136

8.  Characterization of a single-chain variable fragment recognizing a linear epitope of aβ: a biotechnical tool for studies on Alzheimer's disease?

Authors:  Silke Dornieden; Andreas Müller-Schiffmann; Heinrich Sticht; Nan Jiang; Yeliz Cinar; Michael Wördehoff; Carsten Korth; Susanne Aileen Funke; Dieter Willbold
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 9.  Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.

Authors:  Liang Huang; Xiaomin Su; Howard J Federoff
Journal:  Int J Mol Sci       Date:  2013-09-17       Impact factor: 5.923

Review 10.  Recombinant Antibody Fragments for Neurodegenerative Diseases.

Authors:  Karen Manoutcharian; Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.